NIDA has published a series of Frequently Asked Questions (FAQs) about Investigational New Drug (IND) applications for studies of electronic cigarettes (e-cigarettes) in humans. This FAQ helps investigators determine the need for submitting an IND to FDA, and outlines steps to get the process started. Because FDA makes determinations about investigational new drug applications (INDs) on a case-by-case basis, investigators should discuss their study protocol with FDA regarding any questions on whether the IND requirements apply to their planned clinical investigation. This document does not take the place of Institutional Review Board (IRB) requirements, FDA regulations, or NIH policies.
In addition to the research that the Center for Tobacco Products (CTP) supports though the NIH, CTP also conducts its own research and supports research projects through partnerships with different governmental agencies such as the Centers for Disease Control and FDA's National Center for Toxicological Research. To learn more about CTP's full research portfolio, CTP has a research project search tool that provides access to information about the research projects in CTP's research portfolio. Currently, this tool includes active research projects funded by CTP's Office of Science in fiscal years 2010–2015. Subsequent updates to the tool will include projects funded in previous years, new projects, and projects funded by other CTP offices. This tool includes research-based projects only, and does not include those that support infrastructure purchases such as equipment.
Meet some of the people who are leading important tobacco regulatory research. In their own words, they share the work they are doing, and not only why it is so important to public health, but also to each of them personally.
These 10 videos in the series represent a cross section of the work under way around a variety of topics, including perceptions and misperceptions of tobacco products, use of tobacco products and preferences of tobacco users, and the behavioral and physiological effects of using various tobacco products.
*The opinions in these videos reflect the views of individual researchers, and not necessarily the official position of the FDA's Center for Tobacco Products nor the National Institutes of Health. These videos represent accurate information about the design of these CTP supported studies at the time the interviews were conducted (Spring 2014).
"E-cigarettes: Back to the Future," Lecture by Stanton Glantz, University of California, San Francisco. National Institute of Dental and Craniofacial Research Clinical Research Fellowship Grand Rounds, March 15, 2015
Promoted as a safer alternative to conventional cigarettes, the use of e-cigarettes has grown rapidly. This growth in e-cigarette users—particularly among teens and young adults—raises the question of how to respond to the introduction of a new product when the possible health and behavioral effects have not been defined. Dr. Glantz's presentation reviews what is known about the health and behavioral effects of e-cigarettes and identifies important determinants of the long-term population health impacts of e-cigarettes.
Information on a February 29, 2012, webcast discussing the FDA's CTP Research Program priorities, how federal agencies can coordinate tobacco product research, and how non-government organizations can contribute to advancing tobacco product research.
On June 20, 2014, the Tobacco Regulatory Science Program (TRSP) held a webinar for researchers on submitting comments to the FDA Docket. The webinar discussed the public comment/docket process and suggestions on submitting comments for public record on proposed FDA regulation. Allison Hoffman, Ph.D., Associate Director for Science Coordination and Communication, Center for Tobacco Products, FDA presented and answered questions.
FDA recently published the proposed rule Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products (Federal Register / Vol. 79, No. 80 / Friday, April 25, 2014). With this publication, tobacco regulatory scientists have had questions about submitting comments to the docket—a process unfamiliar to many researchers. This webinar:
More information about the proposed rule and resources can be found at the sites below:
Several webinar participants asked questions about submitting comments to dockets—here are some helpful links where interested persons can find more information about how to submit as well as answers to frequently asked questions: Comment on Proposed Regulations and Submit Petitions and Regulations.gov Frequently Asked Questions. If interested persons have further questions about the comment process they can contact FDA Dockets Management, (301) 827-6860. Hours are 9 a.m. to 4 p.m., Eastern time, Monday through Friday.
Tobacco Products Scientific Advisory Committee (TPSAC) advises the Commissioner or designee in discharging responsibilities as they relate to the regulation of tobacco products. The Committee reviews and evaluates safety, dependence, and health issues relating to tobacco products and provides appropriate advice, information and recommendations to the Commissioner of Food and Drugs.